CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding in the Company through recent open-market purchases of 105,824 shares. This is on top of 187,500 shares which he holds personally, bringing his personal stake in CytoMed to 2.50% as of today. In addition, our Chairman is also a 55% shareholder of Glorious Finance Limited, and the sole shareholder of EP Capital Inc, representing 2,282,422 shares, or 19.45% of the Company. In aggregate, he owns 2,388,246 shares representing 21.95% of the Company’s total outstanding shares.

Read more at globenewswire.com